Ivermectin is an antiparasitic drug approved for the treatment of parasitic infections, including strongyloidiasis and onchocerciasis in humans. There is a reported increase in the use of ivermectin for the prevention and treatment of COVID-19 by the public in African Union Member States. Currently, there is: 1. No scientific evidence from pre-clinical studies on the therapeutic effect of ivermectin for the management of COVID-19; 2. No evidence of its clinical efficacy for the management of patients with asymptomatic, mild, moderate or severe COVID-19; and 3. No safety data regarding the use of ivermectin for COVID-19 in the majority of the published studies.